Philip J.  Vickers net worth and biography

Philip Vickers Biography and Net Worth

Director of AVROBIO
Dr. Philip J. Vickers, Ph.D., serves as Director of the Company. Dr. Vickers is the president and chief executive officer and a member of the board of directors of Northern Biologics Inc., a biotechnology company, and has served in such roles since November 2017. From June 2013 until June 2017, Dr. Vickers served as global head of research and development and a member of the executive committee of Shire plc, a biotechnology company focused on the development of therapies for the treatment of rare and specialty conditions. From October 2010 to September 2013, Dr. Vickers served as the senior vice president, head of research and development, human genetic therapies at Shire. Prior to Shire, Dr. Vickers held positions of increasing responsibility in research and development at Merck & Co., Inc., Pfizer Inc., Boehringer-Ingelheim International GmbH and Resolvyx Pharmaceuticals, Inc. Dr. Vickers serves on the board of directors of Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company, and as a scientific advisor to the PTEN Research Foundation. Dr. Vickers obtained his Ph.D. in biochemistry from the University of Toronto, which was followed by postdoctoral research in mechanisms of multidrug resistance in breast cancer at the National Cancer Institute in Bethesda, Maryland.

How do I contact Philip J. Vickers?

The corporate mailing address for Dr. Vickers and other AVROBIO executives is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. AVROBIO can also be reached via phone at (617) 914-8420 and via email at [email protected]. Learn More on Philip J. Vickers' contact information.

Has Philip J. Vickers been buying or selling shares of AVROBIO?

Philip J. Vickers has not been actively trading shares of AVROBIO during the last ninety days. Learn More on Philip J. Vickers' trading history.

Philip J. Vickers Insider Trading History at AVROBIO

See Full Table

Philip J. Vickers Buying and Selling Activity at AVROBIO

This chart shows Philip J. Vickers's buying and selling at AVROBIO by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AVROBIO Company Overview

AVROBIO logo
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.28
Low: $1.25
High: $1.30

50 Day Range

MA: $1.30
Low: $1.15
High: $1.37

2 Week Range

Now: $1.28
Low: $0.57
High: $1.70

Volume

104,197 shs

Average Volume

317,367 shs

Market Capitalization

$57.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24